{
  "abstract": "Background and Importance Aim and Objectives Analyse the effectiveness, safety, and need for retreatment with monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP) in patients with chronic or episodic migraine after completion of a first therapeutic cycle.Material and Methods Observational, retrospective, single-centre, multidisciplinary study in patients who started treatment with anti-CGRP (galcanezumab/erenumab/fremanezumab/eptinezumab) between February 2022 and February 2024 in a tertiary hospital. Demographic variables: sex, age, and type of migraine. To assess effectiveness, monthly migraine days (MMD), HIT-6 and MIDAS scales were analysed at baseline and at 12 months of follow-up after the first cycle, as well as at the start of retreatment and at 6 months. Treatment duration and time to retreatment were taken into account. Safety was assessed by the incidence of adverse reactions (AR).Results A total of 124 patients were included, 88% (109) were women, with a median age of 46 years. 79% (98) were diagnosed with chronic migraine. 37.9% (47) received galcanezumab, 44.4% (55) fremanezumab, 15.3% (19) erenumab, and 2.4% (3) eptinezumab.First cycle efficacy: The median baseline MMD was 12 (10–15.5), HIT6 was 67 (65.5–74), and MIDAS was 63 (26.5–110.5). The response at 12 months was 5 (-58.3%), 48 (-32.8%), and 22 (-65%), respectively.75.8% (94) patients completed treatment according to protocol criteria. 15.3% (19) discontinued due to lack of efficacy and 8.87% (11) for other reasons. Of the 94 patients, 89.4% (84) required retreatment with a median time of 3.4 months. (3 – 3.7)Regarding restarting treatment, the median baseline MMD was 11.56 (9-14.5) (-3.7% from baseline), HIT6 64.4 (60.75-68) (-3.9%), and MIDAS 48.85 (19.5-90) (-22.5%). Six-month follow-up data were available for 73% of patients: 5 (4-6) (-56.77%), 58.6 (55-62.75) (-9.1%), and 23.67 (11-30) (-51.55%), respectively.16.13% (20) experienced adverse reactions, mainly gastrointestinal (45%, 9), followed by neurological (20%, 4) and dermatological (35%, 7). Six patients discontinued treatment due to adverse effects.Conclusion and Relevance The treatment is well tolerated and effective; however, once it is discontinued, its effectiveness is not maintained, and 90.48% of patients must restart treatment.These findings support the need for more individualised strategies in migraine management with anti-CGRP.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain"
      ],
      "name": "E Chilet Rodrigo"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain"
      ],
      "name": "E Fernandez Alonso"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain"
      ],
      "name": "M Gimeno Gracia"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain"
      ],
      "name": "JM Vinuesa Hernando"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Neurologia, Zaragoza, Spain"
      ],
      "name": "S Santos Lasaosa"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Neurologia, Zaragoza, Spain"
      ],
      "name": "E Del Pozo Para"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain"
      ],
      "name": "A Pinilla Rello"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain"
      ],
      "name": "M Perez Huerga"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain"
      ],
      "name": "R Simal Lopez"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain"
      ],
      "name": "AM Lopez Nicolas"
    },
    {
      "affiliations": [
        "Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain"
      ],
      "name": "T Salvador Gomez"
    }
  ],
  "title": "5PSQ-129 Effectiveness and need for retreatment with anti-CGRP antibodies in patients with chronic and episodic migraine",
  "uid": "6dcfc7c6-458d-5dbd-82a6-beff680f4eab"
}